Global Hereditary Angioedema (HAE) Market Size, Share & Trends Analysis Report By Treatment Type (On-Demand/Acute Treatment, Long-Term Prophylaxis, Short-Term Prophylaxis), By Drug Class (Plasma-Derived & Recombinant C1 Esterase Inhibitors, Plasma Kallikrein Inhibitors, Bradykinin B2 Receptor Antagonists, Factor XIIa Inhibitors, Gene & RNA-Based Therapies), By Route of Administration (Intravenous, Subcutaneous, Oral), By Patient Type (HAE Type I & II, HAE with Normal C1-INH, Pediatric, Adult), By End-User (Hospitals & Specialty Clinics, Specialty Pharmacies & Ambulatory Infusion Centers, Home Healthcare), and By Region (North America, Europe, Asia Pacific, Middle East & Africa, Latin America) - Forecasts, 2026-2034.

Table of Contents

1. Introduction

1.1. Market Introduction
1.2. Research Methodology
1.3. Estimation Methodology
1.4. Hereditary Angioedema Treatment Ecosystem Overview
1.5. Market Classification & Scope
1.6. Geographic Scope
1.7. Study Years

2. Market Dynamics

2.1. Drivers: Rising Diagnosis Rates, Cascade Family Screening, Shift Toward Long-Term Prophylaxis
2.2. Restraints: High Treatment Costs, Reimbursement Barriers, Unequal Global Access
2.3. Opportunities: Gene Editing & RNA Silencing, Next-Generation Oral Therapies, Durable Disease Control

3. Market Segmentation (2025–2034)

3.1. By Treatment Type
3.2. By Drug Class
3.3. By Route of Administration
3.4. By Patient Type
3.5. By End-User
3.6. By Region

4. Regional Overview

4.1. North America
4.2. Europe
4.3. Asia Pacific
4.4. Middle East & Africa
4.5. Latin America

5. Competitive Analysis

5.1. Market Share Analysis
5.2. Product Portfolio & Pipeline Benchmarking
5.3. Mechanism of Action & Technology Positioning
5.4. Strategic Partnerships, Licensing & Lifecycle Management

6. Technology & Innovation Trends

6.1. Plasma Kallikrein Inhibition Technologies
6.2. Factor XIIa-Targeted Therapies
6.3. Oral Small-Molecule HAE Therapies
6.4. Gene Editing, RNA Silencing & Durable Disease Control

7. Regulatory Landscape

7.1. Orphan Drug Designation & Rare Disease Regulatory Pathways
7.2. FDA & EMA HAE Treatment Approvals
7.3. Pricing, Reimbursement & Health Technology Assessment
7.4. Pediatric Extensions & Long-Term Safety Requirements

8. Market Research Findings & Conclusion

9. Disclaimer